4.96 (-%)
As of Nov 20, 2024
Source:
Solid Biosciences Inc is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene therapy candidate, for the treatment of Duchenne muscular dystrophy, or Duchenne; AVB-202-TT, a gene therapy program for the treatment of Friedreich’s ataxia, or FA; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and additional assets for the treatment of undisclosed cardiac diseases.
Country | United States |
Headquarters | charlestown, massachusetts |
Phone Number | 617-337-4680 |
Industry | manufacturing |
CEO | Alexander Cumbo |
Website | solidbio.com |